ReviewNeuro-oncology2014
The rationale for targeted therapies in medulloblastoma.
Review in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 65 citations in OpenAlex.
- Targeting Ion Channels: Blockers Suppress Calcium Signals and Induce Cytotoxicity Across Medulloblastoma Cell Models.Bioengineering (Basel, Switzerland) · 2025Article
- Advances on Epigenetic Drugs for Pediatric Brain Tumors.Current neuropharmacology · 2023Review
- The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro.Journal of cellular and molecular medicine · 2022Article
- A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis.Scientific reports · 2021Article
- Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma.Scientific reports · 2021Article
- Review
- Typical Pediatric Brain Tumors Occurring in Adults-Differences in Management and Outcome.Biomedicines · 2021Review
- Modeling SHH-driven medulloblastoma with patient iPS cell-derived neural stem cells.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma.Frontiers in genetics · 2020Article
- Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.BMC cancer · 2019Article
- Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics.Bioengineering (Basel, Switzerland) · 2018Review
- Subfrontal recurrence after cerebellar medulloblastoma resection without local relapse: case-based update.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2018Review
- The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
- Targeting mTOR as a Therapeutic Approach in Medulloblastoma.International journal of molecular sciences · 2018Review
- Medulloblastoma in the Molecular Era.Journal of Korean Neurosurgical Society · 2018Review
- Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy.Oncotarget · 2018Article
- Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors.Molecular diagnosis & therapy · 2018Review
- Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.Current neuropharmacology · 2018Review
- Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Medulloblastoma (MB) is the most frequent malignant brain tumor in children. Patients with MB who are classified as having high-risk disease or those with recurrent disease respond poorly to current therapies and have an increased risk of MB-related mortality. Preclinical studies and molecular profiling of MB tumors have revealed upregulation or activation of several key signaling pathways such as the sonic hedgehog and WNT pathways. Although the exact mechanisms underlying MB tumorigenesis remain poorly understood, inhibiting these key pathways with molecularly targeted therapies represents an important approach to improving MB outcomes. Several molecularly targeted therapies are already under clinical investigation in MB patients. We discuss current preclinical and clinical data, as well as data from clinical trials of targeted therapies that are either ongoing or in development for MB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.